Friday, March 24, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Systems-Based Neurotechnology for Emerging Therapies – SUBNETS

by Global Biodefense Staff
November 11, 2013

The Defense Advanced Research Projects Agency (DARPA) seeks to develop a new understanding of complex, systems-based disorders of the brain and deliver a platform technology for precise therapy in humans living with neuropsychiatric and neurologic disease, including veterans and active duty soldiers suffering from mental health issues.

Methods developed through the “Systems-Based Neurotechnology for Emerging Therapies (SUBNETS)” program will use neural recording and stimulation to close the loop on therapeutic treatment in individuals who receive minimal benefits from currently available treatments.

The program is anticipated to lead to improved knowledge of multiple neural subnetworks of the brain that are involved in disease and illness. The effort combines novel device development, complex modeling of behaving human neural systems, clinical neurology, and animal research in order to advance the understanding and translation of safe, effective neurotechnological therapies.

 “The neuropsychiatry problem is significant to the DoD and requires significant, cooperative investments across technological areas where DARPA has both particular interest and past expertise and development,” states the announcement.

For purposes of this program, DARPA is specifically interested in evaluating the underlying systems, which contribute to the following conditions as described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V): Post-Traumatic Stress Disorder (PTSD); Major Depression; Borderline Personality Disorder; and General Anxiety Disorder.

DARPA is additionally interested in evaluating the representation in the central nervous system for TBI, Fibromyalgia/Chronic Pain, and Substance Abuse.

Further details are available under Solicitation Number: DARPA-BAA-14-09.

Tags: Animal ModelsBAADARPA

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC